Ocera Therapeutics, Inc. (NASDAQ: OCRX) is a clinical stage biopharmaceutical companyfocused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver disease. Ocera’s lead program, OCR-002 (ornithine phenylacetate) is an ammonia scavenger, designed to treat hyperammonemia (elevated ammonia in the blood) and associated hepatic encephalopathy, a complication of patients with liver cirrhosis and acute liver failure or injury. For more information, visit the company’s website atwww.ocerainc.com.